Equities researchers at Wedbush lifted their target price on shares of GTx (NASDAQ: GTXI) from $6.00 to $9.00 in a research report issued on Monday, Analyst Ratings Network reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 28.57% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of GTx in a research note to investors on Thursday. They now have a $8.00 price target on the stock, up previously from $6.00. Analysts at Stifel Nicolaus initiated coverage on shares of GTx in a research note to investors on Friday, April 5th. They set a “buy” rating and a $7.00 price target on the stock.
GTx (NASDAQ: GTXI) traded up 4.95% on Monday, hitting $7.00. GTx has a 52-week low of $2.62 and a 52-week high of $5.41. The stock’s 50-day moving average is currently $4.37. The company’s market cap is $440.6 million.
GTx (NASDAQ: GTXI) last issued its quarterly earnings data on Friday, May 3rd. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.21) by $0.01. During the same quarter in the prior year, the company posted ($0.18) earnings per share. The company’s quarterly revenue was down 100.0% on a year-over-year basis. On average, analysts predict that GTx will post $-0.83 earnings per share for the current fiscal year.
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that targets hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with Analyst Ratings Network's FREE daily email newsletter.